Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age
NCT07013487Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Primary completion
- Oct 2031
- Countries
- 7
01
Overview
A Phase 3 trial of TetraVax-DV in dengue fever, sponsored by Merck & Co.. Started Jun 2025; status: active, not recruiting.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT07013487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013487.